OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce glycated hemoglobin (HbA(1c)), but randomized controlled trial data on their combined use are limited. The LIRA-ADD2SGLT2i trial compared the effect on glycemic control of liraglutide...

Descripción completa

Detalles Bibliográficos
Autores principales: Blonde, Lawrence, Belousova, Lidia, Fainberg, Udi, Garcia-Hernandez, Pedro, Jain, Sunil, Kaltoft, Margit, Mosenzon, Ofri, Nafach, Jalal, Palle, Mads, Réa, Rosangela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554790/
http://dx.doi.org/10.1210/js.2019-OR22-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554790/
http://dx.doi.org/10.1210/js.2019-OR22-1

Ejemplares similares